2d illustrations and photos
Malaysian biotech CytoMed Therapeutics (GDTC) has filed for a proposed $15M initial public offering.
CytoMed didn’t state in its filing the number and price of the shares it intends to offer but did indicate in an attached filing fee schedule that it was looking to raise around $15M.
The company hopes to list its shares on Nasdaq under the symbol GDTC. The Benchmark Co. and Axiom Capital Management are serving as lead bookrunners.
Incorporated in Singapore, CytoMed conducts most of its operations in Malaysia. The company has been developing cell-based immunotherapies for treating cancer. It hopes to use proceeds from the IPO to advance two lead drug candidates into Phase 1 testing.
A pre-clinical stage company, CytoMed is currently operating in the red. For the six-month period ended June 30, CytoMed reported a net loss of $1M and no revenue.
For more IPO News, check out SA’s IPO News page.
